News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Surgical extent impacts the value of the established prognosticators in glioblastoma patients: a prospective translational study in Asia.

Al's Comment:

 I know it sounds obvious that the more tumor you take out the better the patient will do, but it was never really proven before. This is the most convincing evidence yet, and shows the importance of the 5-ALA dye and the brain tumor paint that I have been talking about recently.  Both of these allow the surgeon to see where the tumor is and result in a more complete resection.  Both are not yet approved in the USA.  5-ALA is approved and used routinely in Europe and in trials in the USA.Tumor paint is in early trials in the USA.


Posted on: 12/20/2012

Head Neck Oncol. 2012 Nov 23;4(4):80.
Surgical extent impacts the value of the established prognosticators in glioblastoma patients: a prospective translational study in Asia.
Wang Y, Li S, Zhang Z, Chen X, You G, Yang P, Yan W, Bao Z, Yao K, Wang L, Li M, Jiang T.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China. The Vivian L. Smith Department of Neurosurgery, University of Texas Medical School at Houston, Houston, TX, USA.

Abstract
BACKGROUND:
While multimodal treatments have survival benefits in patients with glioblastoma, tumour volume resection still remains the most effective treatment.

METHODS:
In this prospective translational study, we analysed the clinical values of the established survival predictors in the context of extensive tumour resection (at least near-total resection) in 234 newly diagnosed glioblastoma patients. Common survival factors such as adjuvant therapy modality, O6-methylguanine DNA methyltransferase (MGMT) and isocitrate dehydrogenase 1 (IDH1) were analysed.

RESULTS:
The more extensive resection resulted in a favourable outcome, especially the median progression-free survival up to 11.1 months. Age at diagnosis, the initial alkylating radiochemotherapy and MGMT promoter status were correlated with survival in univariate analysis, but their independent predictive values were lost upon multivariate analysis. Multivariate analysis identified the only independent prognosticators for a longer overall survival were gross total resection (relative risk [RR] = 0.36; P = 0.003) and higher Karnofsky Performance Status score (RR = 0.41; P = 0.008), and gross-total resection (RR = 0.56; P = 0.050), higher Karnofsky Performance Status score (RR = 0.52; P = 0.028) and IDH1 mutation (RR = 0.42; P = 0.011) for a favourable progression-free survival. Interestingly, in the subgroup of patients receiving gross-total resection, neither MGMT nor IDH1 effectively predicted overall survival or progression-free survival; and also radiotherapy alone did not significantly improve the outcome though alkylating radiochemotherapy showed a strong survival advantage. Further analysis showed an additive effect of surgical extent and molecular predictor IDH1 mutation.

CONCLUSION:
Surgical extent most significantly impacts the value of molecular and clinical predictors, and therefore should be taken into full account when assessing a new therapy or stratification variable in glioblastoma multiformes.

PMID: 23250152 [PubMed - in process]

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740